Neurizon Therapeutics has reported positive topline results from an open-label extension (OLE) study of its lead candidate ...

ROME, AUG 19 - An Italo-US team of scientists have made a breakthrough in the early diagnosis of amyotrophic lateral ...

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

SineuGene gets China NMPA & US FDA nods to initiate phase I/IIa trial of gene therapy, SNUG01 to treat amyotrophic lateral sclerosis: Beijing Monday, August 18, 2025, 18:00 Hrs [I ...

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...

Amyotrophic lateral sclerosis (ALS) is a widespread neurodegenerative disease caused by the loss of neurons that control movement. Although abnormal accumulation of proteins called TDP-43 ...

Stanford University scientists have developed a brain implant designed to "hear" and vocalize words a person with severe ...

"New therapeutic strategy to reduce neuronal death in amyotrophic lateral sclerosis." ScienceDaily. ScienceDaily, 16 November 2023. <www.sciencedaily.com / releases / 2023 / 11 / 231116141023.htm>.

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.